Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00358436 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 804
- Enrollment target
NCT00358436 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 804 participants.
The verdict
NCT00358436, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 804 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.
Interventions
- DRUG Placebo
- DRUG Aclidinium bromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 804 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00358436
The ClinicalTrials.gov registry entry for NCT00358436 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 804 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00358436 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00358436 about?
NCT00358436 is a clinical study titled "Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)". To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.
What is the current status of trial NCT00358436?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 804 participants. The study started on 2006-08. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00358436?
The interventions under investigation include: Placebo (DRUG), Aclidinium bromide (DRUG).
Who is sponsoring clinical trial NCT00358436?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.